Gene hunt aims to predict deadly diabetes drug complication

NCT ID NCT05402579

Completed Knowledge-focused Sponsor: Mount Sinai Hospital, Canada Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a person's genes can help predict their risk of diabetic ketoacidosis (DKA) when taking SGLT2 inhibitors, a common class of diabetes drugs. Researchers collected DNA from 63 adults with type 2 diabetes who were either hospitalized with DKA while on the drug or were taking it without DKA. The goal was to find genetic variants that might explain why some people develop this life-threatening side effect.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: genomic analysis
What this could lead to: If successful, this could help doctors identify who is at higher risk of diabetic ketoacidosis when taking SGLT2 inhibitors, making the drugs safer to use.
What could go wrong: This was a small, completed study with only 63 participants. The findings are exploratory and may not lead to a usable test without much larger validation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetic ketoacidosis type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES TYPE 2 DIABETIC KETOACIDOSIS DKA

Contacts and locations

Locations

St. Joseph's Health Centre (Unity Health Toronto)

Toronto, Ontario, Canada
Toronto General Hospital (University Health Network)

Toronto, Ontario, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.